4SC AG (VSC) - Financial and Strategic SWOT Analysis Review

Document Sample
4SC AG (VSC) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					                  4SC AG (VSC) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH55969FSA                                                                                          Publication Date: MAY 2012

          Am Klopferspitz 19a                                Phone              +49 89 7007630                  Revenue          0.80 (million EUR)
          Martinsried                                        Fax                +49 89 70076329                 Net Profit       -19.07 (million EUR)
          82152                                              Website            www.4sc.de                      Employees        96
                                                                                                                                 Pharmaceuticals           &
          Germany                                            Exchange           VSC [XETRA]                     Industry
                                                                                                                                 Healthcare

       Company Overview
       4SC AG (4SC) is a research oriented company that focuses on the development of innovative products for treatment of cancer
       and auto-immune disorders. It is an early stage development company with six molecules in the pipleline in various stages of
       development. Its lead products resminostat and vido?udimus are in Phase II trials. Resminostat, a pan-histone deacetylase
       (HDAC) inhibitor, is in trial for various oncology indications including colorectal cancer, lymph node cancer (Hodgkin’s lymphoma)
       and liver cancer (HCC). The company partners with Yakult Honsha for the development and commercialization of resminostat.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      4SC AG, SWOT Analysis
         Dr Ulrich Dauer                     Chief Executive Officer                  Strengths                              Weaknesses
         Dr. Joerg Neermann                  Chairman,          Supervisory
                                                                                      Patent Portfolio                       Lack of manufacturing facilities
                                             Board
         Dr. Manfred Ruediger                Director                                 4SCan Technology                       Weak Financial Position
         Dr. Clemens Doppler                 Director
         Guenter Frankenne                   Director                                 Opportunities                          Threats
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Robust Product Pipeline                Industry Consolidation

       Share Data                                                                     Market Potential – Oncology            Uncertain R&D Outcomes
         4SC AG
        Share Price (EUR) as on 27-Apr-                                  2.27        Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        2012
        EPS (EUR)                                                       -0.46
        Market Cap (million EUR)                                           99
        Enterprise Value (million EUR)                                     92
        Shares Outstanding (million)                                       42
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Apr 18, 2012         4SC Discovery And Crelux Enter Into Strategic
                                                                                                           Alliance For Joint Drug Discovery Services
                                                                                      Dec 14, 2011         4SC Forms Subsidiary To Commercialize
                                                                                                           Early-Stage Drug Research
                                                                                      Nov 07, 2011         4SC Reports Q3 2011 Results
                                                                                      Aug 09, 2011         4SC Reports Q2 2011 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




4SC AG (VSC) - Financial and Strategic SWOT Analysis Review                                                                    Reference Code: GDPH55969FSA
Source : www.globalcompanyintelligence.com                                                                                                                      Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       4SC AG - Key Facts ........................................................................................................................................................................... 5
       4SC AG - Key Employees .................................................................................................................................................................. 6
       4SC AG - Key Employee Biographies ................................................................................................................................................ 7
       4SC AG - Major Products and Services ............................................................................................................................................. 8
       4SC AG - Pharmaceutical Pipeline Products Data ............................................................................................................................. 9
          4SC AG, Pipeline Products by Therapy Area ................................................................................................................................. 9
          4SC AG, Pipeline Products by Development Phase ..................................................................................................................... 10
       4SC AG - History .............................................................................................................................................................................. 13
       4SC AG - Company Statement ........................................................................................................................................................ 15
       4SC AG - Locations And Subsidiaries .............................................................................................................................................. 18
          Head Office ................................................................................................................................................................................... 18
       Section 2 – Company Analysis ......................................................................................................................................................... 19
       4SC AG - Business Description........................................................................................................................................................ 19
       4SC AG - Corporate Strategy ........................................................................................................................................................... 20
       4SC AG - SWOT Analysis ................................................................................................................................................................ 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          4SC AG - Strengths ...................................................................................................................................................................... 21
             Strength - Patent Portfolio ......................................................................................................................................................... 21
             Strength - 4SCan Technology ................................................................................................................................................... 21
             Strength - Reminostat - Orphan Drug Status ............................................................................................................................ 21
          4SC AG - Weaknesses ................................................................................................................................................................. 21
             Weakness - Lack of manufacturing facilities ............................................................................................................................. 21
             Weakness - Weak Financial Position ........................................................................................................................................ 21
          4SC AG - Opportunities ................................................................................................................................................................ 22
             Opportunity - Robust Product Pipeline ...................................................................................................................................... 22
             Opportunity - Market Potential – Oncology................................................................................................................................ 22
             Opportunity - Emerging Markets ............................................................................................................................................... 22
             Opportunity - Partnership With Yakult ....................................................................................................................................... 22
          4SC AG - Threats ......................................................................................................................................................................... 23
             Threat - Industry Consolidation ................................................................................................................................................. 23
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 23
             Threat - Growing Parallel Trade ................................................................................................................................................ 23
       4SC AG - Key Competitors............................................................................................................................................................... 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30



4SC AG (VSC) - Financial and Strategic SWOT Analysis Review                                                                                                    Reference Code: GDPH55969FSA
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ............................................................................... 30
          4SC AG, Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 .............................................................................. 31
       4SC AG, Recent Deals Summary .................................................................................................................................................... 32
       Section 5 – Company’s Recent Developments .............................
				
DOCUMENT INFO
Description: 4SC AG (4SC) is a research oriented company that focuses on the development of innovative products for treatment of cancer and auto-immune disorders. It is an early stage development company with six molecules in the pipleline in various stages of development. Its lead products resminostat and vido?udimus are in Phase II trials. Resminostat, a pan-histone deacetylase (HDAC) inhibitor, is in trial for various oncology indications including colorectal cancer, lymph node cancer (Hodgkin’s lymphoma) and liver cancer (HCC). The company partners with Yakult Honsha for the development and commercialization of resminostat. Vido?udimus is indicated for the treatment of inflammatory bowel disease and rheumatoid arthritis. The company is also conducting research programs related to cancer stem cells, ion channel blockers and cycotine modulation. 4SC is headquartered in Martinsried, Germany. 4SC operates with the strategic intent of developing novel products for the treatment of cancer and autoimmune disorders with particular focus on its lead products, Vidofludimus, reminostat and 4SC 202. As a part of its efforts to concentrate on research and development, the company created a subsidiary, 4SC Discovery GmbH. The subsidiary facilitates greater flexibility for collaborations with leading pharmaceutical and biotech companies in the pharma industry.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.